Výsledky vyhledávání - "Antineoplastic Agents, Phytogenic/adverse effects"

Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?

Autor: Stijn L.W. Koolen, Nielka P. van Erp, Ron H.J. Mathijssen, Thomas P. C. Dorlo, Marie-Rose B S Crombag, Sophie Wijngaard, Jos H. Beijnen, Alwin D. R. Huitema, Markus Joerger

Publikováno v: Pharmaceutical Research, 36(12):163. Springer New York
Pharmaceutical Research, 36
Pharmaceutical Research, 36, 12
Pharmaceutical Research, 36(12). Springer New York
Pharmaceutical Research, 36(12). Springer New York LLC

Purpose: There is ongoing concern regarding increased toxicity from paclitaxel in elderly patients, particularly of severe neutropenia. Yet, data so far is controversial and this concern is not supported by a clinically relevant age-dependent differe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7904b264257684f3d6a38f5748e3b8a
https://pure.eur.nl/en/publications/e144242d-e111-4d2b-8a55-7c6512fff05f

Zobrazit plný text záznamu

A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small Cell Lung Cancer: A Randomized Trial

Autor: Leyvraz, S., Pampallona, S., Martinelli, G., Ploner, F., Perey, L., Aversa, S., Peters, S., Brunsvig, P., Montes, A., Lange, A., Yilmaz, U., Rosti, G., Marrow, Transplantation

Publikováno v: Journal of the National Cancer Institute, vol. 100, no. 8, pp. 533-541

BACKGROUND: The dose intensity of chemotherapy can be increased to the highest possible level by early administration of multiple and sequential high-dose cycles supported by transfusion with peripheral blood progenitor cells (PBPCs). A randomized tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b94d9825381050dae08a1ce9fb3198bf
https://doi.org/10.1093/jnci/djn088

Zobrazit plný text záznamu

Docetaxel (TaxotereTM) is active in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG)

Autor: Cerny, T., Kaplan, S., Pavlidis, Nicholas, Schöffski, P., Epelbaum, R., Meerbeek, J. van, Wanders, J., Franklin, H. R., Kaye, Stanley B.

Publikováno v: The British journal of cancer
British Journal of Cancer
British journal of cancer

In a multicentre trial of the EORTC ECTG we have treated 43 non-pretreated patients with advanced non-small-cell lung cancer (NSCLC) with the new semisynthetic taxoid docetaxel (Taxotere). Six patients were ineligible; of the 37 eligible patients, te

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bba3154c785aa2edc1e71783fe3ecd9
https://doi.org/10.1038/bjc.1994.311

Zobrazit plný text záznamu

Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group

Autor: Skarlos, Dimosthenis V., Dimopoulos, M. A., Kosmidis, Paraskevas A., Papakostas, P., Pavlidis, Nicholas, Bacoyiannis, Charalambos, Kiamouris, Ch, Klouvas, G. D., Gogas, H., Fountzilas, George, Samantas, E.

Publikováno v: Lung Cancer

There is some evidence that taxanes and gemcitabine are effective antitumor agents against small-cell lung cancer (SCLC). A total of 20 chemotherapy-naive patients with extensive disease (ED) SCLC, were treated as a part of the first step of a phase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bbe21cd86b583306fdd7a4dd37cc674
http://olympias.lib.uoi.gr/jspui/handle/123456789/22384

Zobrazit plný text záznamu

Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support

Autor: Briassoulis, E. Ch, Froudarakis, M. E., Milionis, Haralampos J., Peponis, I. A., Constantopoulos, S. H., Pavlidis, Nicholas

Publikováno v: Respiration

Several cancer therapeutic agents have been associated with pulmonary toxicity. Herein, we describe the case of a 73-year-old woman with breast cancer metastatic to the liver, who developed noncardiogenic pulmonary edema (NPE) while on treatment with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d434fd22cbf4cd74ec4303a5aa2fe35c
https://gnosis.library.ucy.ac.cy/handle/7/41443

Zobrazit plný text záznamu

A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group

Autor: Kosmidis, P., Mylonakis, N., Fountzilas, G., Pavlidis, N., Samantas, E., Karabelis, A., Kattis, K., Skarlos, D.

BACKGROUND: It was recently reported that when ifosfamide was added to cisplatin and vinblastine the response rate was increased but not the survival in patients with non-small-cell lung cancer (NSCLC). The purpose of this study was to investigate th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10561::dfec54cd1271404a35d05fb8829af0e2
http://olympias.lib.uoi.gr/jspui/handle/123456789/24261

Zobrazit plný text záznamu

Successful rechallenge with taxanes following prophylactic ketotifen in patients who had developed severe hypersensitivity reactions

Autor: N. Pavlidis, E. Briasoulis, Vasilios Karavasilis

Publikováno v: Annals of Oncology. 11:899

Medical oncologists are occasionally confronted with the dilemma of early termination of taxane treatment in patients, due to developed of major hypersensitivity reactions (HSRs) despite the administration of anti-allergic premedication. We led a pil

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2333f4b9ab620eeb31b3e56c390914c4
https://doi.org/10.1023/a:1008366801690

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání